İmmunsupresif Tedavi Alan Hastalarda HBV Reaktivasyonu ve Antiviral Profilaksinin Değerlendirilmesi

Abstract

Amaç: Kronik hepatit B’li hastalar ve geçirilmiş hepatit B virüs enfeksiyonu olan kişiler immünsupresif tedavi aldıkları zaman HBV reaktivasyonu riskine maruz kalırlar. Bu çalışmada romatolojik hastalıklar nedeni ile çeşitli immünsupresif tedavileri alan hastaların hepatit B serolojilerini, risk gruplarını ve antiviral profilaksi alma durumlarını sunmayı amaçladık. Gereç ve Yöntem: Çalışmaya Mayıs 2022 ile Mayıs 2023 tarihleri arasında bir eğitim ve araştırma hastanesinde romatolojik hastalıklar nedeni ile tümör nekroz faktör-α inhibitörü, tirozin kinaz inhibitörü, steroid, metotreksat veya anti-CD20 antikoru alan 18 yaş üstü 375 hasta dahil edildi. Hastaların HbsAg, anti-Hbs ve anti-Hbc IgG serolojileri, immünsupresif tedavileri ve süresi ile almış oldukları oral antiviraller retrospektif olarak incelendi. Bulgular: Çalışmaya alınan 375 hastanın yaş ortalaması 43.77±13.07 idi. Hastaların 193’ ü (%51.5) erkek idi. Hastaların 11’ inde HbsAg pozitif, 150’ sinde anti Hbs pozitif, 19’ unda izole anti-Hbc IgG pozitif ve 79 hastada ise anti-Hbs ile anti-Hbc IgG beraber pozitif idi. Serolojik bulgulara göre 109 (%29) hastada HBV ile karşılaşma durumu mevcuttu. 194 (%51.7) hastanın ise her üç tetkik sonucu da negatif idi. Toplamda 85 (%22.7) hasta immünsupresif ajan kullanımı nedeni ile oral antiviral profilaksi almaktaydı. HBV reaktivasyon riski profilaksi başlanan hastaların 14’ ünde (%16.5) yüksek, 64’ ünde (%75.3) orta, 7’ sinde (%8.2) düşük riskliydi. 79 hasta entekavir, 5 hasta tenofovir disoproksil fumarat ve 1 hasta ise tenofovir alafenamid fumarat almakta idi. Ortalama immünsüpresif tedavi alma süresi 6.41±4.20 yıl idi. Hastaların oral antiviral profilaksi alma süreleri ise ortalama 1.02±1.72 yıl idi. HBV reaktivasyonu görülen hastamız olmadı. Sonuç: Hastalar immünsupresif tedavi almadan önce hepatit B serolojileri ve profilaksi durumları öncelikle değerlendirilmelidir. Ayrıca koruyucu hekimlik faaliyeti olarak aşısız hastaların en kısa sürede hepatit B aşıları tamamlanmalıdır.

Keywords

• İmmünsupresyon
• hepatit B
• reaktivasyon

Evaluation of HBV Reactivation and Antiviral Prophylaxis in Patients Receiving Immunosuppressive Therapy

Abstract

Aim: Patients with chronic hepatitis B and people with a history of hepatitis B (HBV) infection are at risk of HBV reactivation (HBVr) when they receive immunosuppressive therapy. In this study, we aimed to evaluate the hepatitis B serology, risk groups and antiviral prophylaxis of patients receiving various immunosuppressive therapies due to rheumatological diseases. Material and Method: The study included 375 patients over 18 years of age who received tumor necrosis factor-α (TNF-α) inhibitor, tyrosine kinase inhibitor, steroids, methotrexate or anti-CD20 antibodies due to rheumatic diseases in a training and research hospital between May 2022 and May 2023. Hepatitis B surface antigen (HbsAg), hepatitis B surface antibody (anti-Hbs), hepatitis B core protein antibody (anti-Hbc IgG) serologies, immunosuppressive therapies and oral antivirals were retrospectively analyzed. Results: The average age of the 375 patients included in the study was 43.77±13.07 years. 193 (51.5%) of the patients were male. 11 patients were HbsAg positive, 150 patients were anti-Hbs positive, 19 patients were isolated anti-Hbc IgG positive, and 79 patients were both anti-Hbs and anti-Hbc IgG positive. According to serological findings, 109 (29%) patients had HBV exposure. All three test results of 194 (51.7%) patients were negative. A total of 85 (22.7%) patients received oral antiviral prophylaxis due to the use of immunosuppressive agents. In terms of HBVr, 16.5% were evaluated as high risk, 75.3% as moderate risk, and 8.2% as low risk. Out of 85 patients 79 received entecavir, 5 reveived tenofovir disoproxil fumarate (TDF) and 1 received tenofovir alafenamide fumarate (TAF). The mean duration for the immunosuppressive therapy was 6.41±4.20 years. The mean duration of oral antiviral prophylaxis among patients was 1.02±1.72 years. HBVr was not observed in any of our patients. Conclusion: Before patients receive immunosuppressive therapy, hepatitis B serologies and prophylaxis indication should be evaluated firstly. In addition, as a preventive medicine activity, hepatitis B vaccinations of unvaccinated patients should be completed as quickly as possible.

Keywords

• Immunosuppression
• hepatitis B
• reactivation

References

1. 1. Sono S, Sae-Chan J, Kaewdech A, Chamroonkul N, Sripongpun P. HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program. PLoS One. 2022;17(6):e0270458.
2. 2. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21(11):1020-6.
3. 3. Wu T, Li J, Shao L, Xin J, Jiang L, Zhou Q, et al. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure. Gut. 2018;67(12):2181-91.
4. 4. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148(1):215-9; quiz e16-7.
5. 5. Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M, et al. Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital. Arthritis Research & Therapy. 2019;21(1):255.
6. 6. Mahroum N, Watad A, Tiosano S, Hejly A, Mahagna H, Waknin R, et al. Chronic hepatitis B viral infection among RA patients-a cross-sectional control study. Clin Rheumatol. 2019;38(5):1237-41.
7. 7. Etienne S, Vosbeck J, Bernsmeier C, Osthoff M. Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines. J Gen Intern Med. 2023;38(2):490-501.
8. 8. Aygen B, Demir AM, Gümüş M, Karabay O, Kaymakoğlu S, Köksal A, et al. Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turk J Gastroenterol. 2018;29(3):259-69.

9. 9. Pattullo V. Prevention of Hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22(2):219-37.
10. 10. Karadağ Ö, Kaşifoğlu T, Özer B, Kaymakoğlu S, Kuş Y, İnanç M, et al. Viral hepatitis screening guideline before biological drug use in rheumatic patients. Eur J Rheumatol. 2016;3(1):25-8.
11. 11. Cabalak M, Bal T, Ocak S. İmmünsüpresif Tedavi Alacak Hastalarda Hepatit Serolojisi. Harran Üniversitesi Tıp Fakültesi Dergisi. 2020;17.
12. 12. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98.
13. 13. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-99.
14. 14. Lau G, Yu ML, Wong G, Thompson A, Ghazinian H, Hou JL, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021;15(5):1031-48.
15. 15. Ceylan M, TURKEN M, Singil S, Pelin A, Şükran K. İmmunsupresif Tedavi Alan Hastalarda Hepatit B Reaktivasyonu Riskinin Değerlendirilmesi. İzmir Tıp Fakültesi Dergisi.1(3):112-6.
16. 16. Durak S, Coşar AM. Evaluation of the safety and antiviral efficacy of the tenofovir alafenamide fumarate molecule in immunosuppressed patients. Journal of Health Sciences and Medicine. 2022;5(6):1688-92.
17. 17. Jeong S, Shin HP, Kim HI. Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B. Intervirology. 2022;65(2):94-103.
18. 18. Baranek B, Wang S, Cheung AM, Mishra S, Tan DH. The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis. Antivir Ther. 2020;25(1):21-32.
19. 19. Ha NB, Ku K, Ha NB, Chaung KT, Trinh HN, Nguyen MH. Renal Function in Chronic Hepatitis B Patients Treated With Tenofovir Disoproxil Fumarate or Entecavir Monotherapy: A Matched Case-Cohort Study. J Clin Gastroenterol. 2015;49(10):873-7.
20. 20. Su J, Long L, Zou K. Antiviral prophylaxis for preventing reactivation of hepatitis B virus in rheumatic patients: a systematic review and meta-analysis. Clin Rheumatol. 2018;37(12):3201-14.
21. 21. Picardi M, Della Pepa R, Giordano C, Zacheo I, Pugliese N, Mortaruolo C, et al. Tenofovir vs lamivudine for the prevention of hepatitis B virus reactivation in advanced-stage DLBCL. Blood. 2019;133(5):498-501.
22. 22. Yang C, Qin B, Yuan Z, Chen L, Zhou HY. Meta-analysis of prophylactic entecavir or lamivudine against hepatitis B virus reactivation. Ann Hepatol. 2016;15(4):501-11.
23. 23. Chen M-H, Chen M-H, Liu C-Y, Tsai C-Y, Huang D-F, Lin H-Y, et al. Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment. The Journal of Infectious Diseases. 2016;215(4):566-73.
24. 24. Padovan M, Filippini M, Tincani A, Lanciano E, Bruschi E, Epis O, et al. Safety of Abatacept in Rheumatoid Arthritis With Serologic Evidence of Past or Present Hepatitis B Virus Infection. Arthritis Care Res (Hoboken). 2016;68(6):738-43.
25. 25. Vassilopoulos D, Delicha EM, Settas L, Andrianakos A, Aslanidis S, Boura P, et al. Safety profile of repeated rituximab cycles in unselected rheumatoid arthritis patients: a long-term, prospective real-life study. Clin Exp Rheumatol. 2016;34(5):893-900.
26. 26. Harigai M, Winthrop K, Takeuchi T, Hsieh TY, Chen YM, Smolen JS, et al. Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis. RMD Open. 2020;6(1).
27. 27. Lee YH, Bae SC, Song GG. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int J Rheum Dis. 2013;16(5):527-31.
28. 28. Urata Y, Uesato R, Tanaka D, Kowatari K, Nitobe T, Nakamura Y, et al. Prevalence of reactivation of hepatitis B virus replication in rheumatoid arthritis patients. Mod Rheumatol. 2011;21(1):16-23.
29. 29. Canzoni M, Marignani M, Sorgi ML, Begini P, Biondo MI, Caporuscio S, et al. Prevalence of Hepatitis B Virus Markers in Patients with Autoimmune Inflammatory Rheumatic Diseases in Italy. Microorganisms. 2020;8(11).
30. 30. Makvandi M, Noormandi Pour S, Teimoori A, Shokri S, Mahmoudvand S, Biparva Haghighi S, et al. Frequency of Hepatitis B Markers in Systemic Lupus Erythematosus Patients in Iran. Asian Pac J Cancer Prev. 2022;23(6):1921-6.
31. 31. Cabalak M, Kimyon G, Bal T. Frequency of Hepatitis B Virus Screening in Patients with Systemic Lupus Erythematosus. Mediterranean Journal of Infection Microbes and Antimicrobials. 2020;9.
32. 32. Yang S, Tian G, Cui Y, Ding C, Deng M, Yu C, et al. Factors influencing immunologic response to hepatitis B vaccine in adults. Sci Rep. 2016;6:27251. 33. Öztürk S, Kaçar M, Toprak S, Çolak O, Öztürk D, Agalar C. Hepatit B Aşılama Verileri; İmmünsüpresif Hastalarda Tek Doz mu? Çift Doz mu? Namık Kemal Tıp Dergisi.8(3):499-506.